takotsubo syndrome

in review 5 min read Updated 2026-10-19
takotsubo syndrome

Catecholamine surge → transient LV dysfunction (classically apical ballooning with basal hyperkinesis) beyond one coronary territory, usually in a post-menopausal woman after a physical or emotional trigger. Presents as ACS — STE → angiography first. In-hospital shock and death rates match ACS; ~1 in 5 has a serious complication. Key acute decisions: look for LVOTO (~20%) before giving inotropes or nitrates, watch QTc (torsades days 2–4), consider anticoagulation for large apical akinesis. ACEi/ARB after discharge; beta-blockers don’t prevent recurrence.

recognition

InterTAK diagnostic criteria:

  1. Transient LV dysfunction — apical (typical), midventricular, basal or focal; RV involved in ~⅓; usually beyond one coronary territory (focal type may fit one)
  2. Emotional, physical or combined trigger — common, not required (~⅓ have none)
  3. Neurological triggers (SAH, stroke/TIA, seizure) and phaeochromocytoma count
  4. New ECG change — ST elevation or depression, TWI, QTc prolongation (rarely none)
  5. Troponin/CK moderately raised; BNP markedly raised
  6. Obstructive CAD does not exclude it (10–29%; WMA extends beyond the stenosed territory)
  7. No infectious myocarditis — CMR to confirm and exclude
  8. Mostly post-menopausal women (~90%, mean 67–70 y)
  • Physical triggers (more common; men): respiratory failure, sepsis, surgery, pancreatitis, thyrotoxicosis, chemotherapy, alcohol/opiate withdrawal, exogenous catecholamines, dobutamine stress, β-agonists.
  • Basal type → think phaeochromocytoma, adrenaline exposure, SAH.
  • 5th UDMI: catecholamine-mediated acute myocardial injury, not MI → myocardial injury and MI classification.

ECG and biomarkers

featuretakotsuboanterior STEMI
ST elevation44%; centred V2–V5, II, aVR (−aVR); less in V1; inferior-only rareV1–V4, I, aVL
ST depression<10%>30% → favours ACS
T waves / QTcprogressive deep, widespread TWI + QTc prolongation over days—
Q waves15%69%
troponinadmission similar to ACS, peak much lower; WMA ≫ necrosis—
BNP / NT-proBNPmarkedly raised, peak 24–48 h—

diagnostic pathway

flowchart TD
  A["chest pain / dyspnoea + ECG change or troponin"] --> B{"ST elevation?"}
  B -- yes --> C["urgent angiography + LV ventriculography"]
  B -- no --> D{"InterTAK score >70?"}
  D -- "≤70 (low/intermediate)" --> C
  D -- ">70 (high, ~90%)" --> E["TTE"]
  E -- "circumferential ballooning, stable" --> F["CCTA to exclude CAD"]
  E -- "no circumferential pattern or unstable" --> C
  C --> G{"culprit lesion explains whole WMA?"}
  G -- yes --> H["ACS"]
  G -- no --> I{"myocarditis red flags?<br/>viral prodrome, ↑ CRP/ESR, effusion"}
  F --> I
  I -- yes --> J["CMR"]
  I -- no --> K["takotsubo → confirm recovery on follow-up echo"]
InterTAK scorepoints
female25
emotional trigger24
physical trigger13
no ST depression (except aVR)12
psychiatric disorder11
neurological disorder9
QTc prolongation6

30 points → <1% probability; 50 → 18%; >70 → ~90%. Not validated for phaeochromocytoma-induced cases.

  • Echo: apical ballooning with basal hyperkinesis; screen every patient for LVOTO, MR (14–25%; SAM or tethering), RV involvement, apical thrombus. LV recovers in 4–8 weeks.
  • CMR (subacute): RWMA + oedema without LGE → separates from infarct (territorial LGE) and myocarditis (epicardial/patchy LGE); superior for RV involvement.
  • CCTA instead of angiography: stable with low ACS suspicion, suspected recurrence, or within critical illness (sepsis, SAH, stroke) or when invasive risk is high.

complications

complicationrate
acute HF12–45%
LVOTO10–25%
MR14–25%
cardiogenic shock6–20%
AF5–15%
LV thrombus2–8%
cardiac arrest4–6%
AV block~5%
torsades / VT / VF3–8.6%
in-hospital death1–4.5%
  • Predictors of in-hospital events: physical trigger, acute neurological or psychiatric illness, admission troponin >10× URL, LVEF <45%; men up to 3× mortality.
  • Malignant arrhythmia peaks days 2–4 with deep anterolateral TWI and QTc >500 ms → pause-dependent torsades → treat as acquired long QT.
  • Long term: death 5.6%/patient-year, MACCE 9.9%/patient-year — comparable to CAD. Recurrence ~5% (3 weeks–4 years; ~1.8%/patient-year), may take a different pattern.

management

Consensus only (evidence level C) — no RCTs.

settingdoavoid
first contacttreat as ACS: ASA, heparin; ECG monitoring—
mild, no HFtelemetry ≥48 h; consider ACEi/ARB, beta-blocker—
pulmonary oedemaACEi/ARB, beta-blocker; diuretic and nitroglycerin only if no LVOTO—
shock with LVOTOIV fluid (if no HF), short-acting beta-blocker, Impellainotropes, diuretics, nitroglycerin, IABP
shock, primary pump failurelevosimendan, Impella, VA-ECMOcatecholamines (adrenaline, noradrenaline, dobutamine, milrinone, isoproterenol) — ~20% mortality on catecholamines
torsades / VT / AV blockconsider beta-blocker; temporary pacing for AV block; wearable defibrillator if QTc very long or VT/VFQT-prolonging drugs; beta-blocker with bradycardia and QTc >500 ms (caution); permanent devices (ICD of uncertain value — reversible)
LV thrombus, or consider if LVEF ≤30% / large apical akinesisheparin → OAC ([[warfarinVKA]] or [[direct oral anticoagulants
  • Beta-blockers may relieve LVOTO but are contraindicated in severe HF with low LVEF, hypotension or bradycardia.
  • After discharge: ACEi/ARB for ≥3 months or until WMA recovers (1-year survival benefit, fewer recurrences — uncertain, needs validation); beta-blockers — no survival benefit, ⅓ recur on them; ASA + statin only if coexisting CAD; psycho-cardiac rehab for depression/anxiety; HRT listed for recurrence prevention in the algorithm, but the text calls oestrogen supplementation questionable.
  • Shock management detail → cardiogenic shock, vasoactive drugs.

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction takotsubo syndrome